New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Again
June 11 2009 - 7:00AM
PR Newswire (US)
COLLEGEVILLE, Pa., June 11 /PRNewswire-FirstCall/ -- New data from
Phase 3 European clinical trials reinforce that Wyeth's (NYSE:WYE)
investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal
Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the
potential to provide coverage against the 13 most prevalent
serotypes associated with pneumococcal disease (PD), the leading
cause of vaccine-preventable death in children younger than five
worldwide. The Phase 3 data presented at the 27th Annual Meeting of
the European Society for Pediatric Infectious Diseases (ESPID) come
from seven core studies in the pediatric clinical trial program for
Prevenar 13 which were conducted in France, Italy, Poland, Spain
and the UK. Researchers also presented health economic models which
estimated the potential public health and economic impact of
Prevenar 13 -- if approved and incorporated into national
immunization programs -- for the Netherlands, the UK, as well as
Germany and the U.S. "Our investigational vaccine, Prevenar 13,
builds on the scientific foundation of Prevenar and is designed to
provide more comprehensive protection against pneumococcal
disease," says Emilio A. Emini, Ph.D., Executive Vice President,
Vaccines Research and Development, Wyeth Pharmaceuticals. "These
new data indicate that Prevenar 13 has the potential to provide
direct coverage of the 13 most common disease-causing serotypes,
including 3, 6A and 19A, which have been increasing in prevalence
in many regions around the world." Prevenar 13 includes the seven
serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) in Prevenar*
(Pneumococcal Polysaccharide Conjugated Vaccine, [Adsorbed]) -- the
current global standard in PD prevention in infants and young
children as well as six additional serotypes (1, 3, 5, 6A, 7F and
19A) associated with the greatest remaining burden of invasive
disease. Both Prevenar 13 and Prevenar use CRM197 -- an
immunological carrier protein with a 20-year history of use in
pediatric vaccines. Phase 3 Data Results Data from the studies
presented at ESPID indicate that Prevenar 13 is immunogenic for all
serotypes and showed a safety profile similar to Prevenar. Among
the study findings: -- In a study conducted in France, 613 children
were randomized to receive either four doses of Prevenar or
Prevenar 13 at 2, 3, 4 and 12 months, or three doses of Prevenar at
2, 3 and 4 months with a booster dose of Prevenar 13 or Prevenar at
12 months. Antibody response was measured at month 13. Both of the
Prevenar 13 schedules induced a robust immune response for all 13
serotypes. -- In a study conducted in Italy, 606 healthy infants
aged 3 months were randomized to receive Prevenar 13 or Prevenar
along with Infanrix hexa(R) [GlaxoSmithKline], the combined
diphtheria, tetanus, pertussis, hepatitis B, inactivated
poliovirus, and Hib vaccine, at 3, 5, and 11 months of age.
Assessment of functional antibody levels (serotype specific
opsonphagocytic assay) one month after the infant series and after
the booster dose showed that a high percentage of infants receiving
Prevenar 13 had functional antibodies for all serotypes. Prevenar
13 did not affect responses to the concomitantly administered
vaccine and showed a safety profile comparable to Prevenar. -- A
study of 352 children in Poland assessed the safety and
immunogenicity of Prevenar 13 in older children not previously
immunized with Prevenar. Children were vaccinated with one of three
different catch-up schedules currently recommended for Prevenar.
These treatment schedules included the following: 1) two doses of
Prevenar 13 at age 7 to
Wyeth (NYSE:WYE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Wyeth (NYSE:WYE)
Historical Stock Chart
From Jul 2023 to Jul 2024